Fengshi Gutong Capsule Attenuates Osteoarthritis by Inhibiting MAPK, NF-κB, AP-1, and Akt Pathways

Background and purpose: Fengshi Gutong capsule (FSGTC), a traditional herbal formula, has been used clinically in China for the treatment of arthritis. However, the mechanism underlying the therapeutic effects of FSGTC on osteoarthritis (OA) has not been elucidated. The present study investigated th...

Full description

Bibliographic Details
Main Authors: Yao-Xin Gao, Hao-Heng Yu, Chuan He, Ming Li, Dan-Dan Guo, Jun-Jiang Lian, Hai-Jie Yang, Mian Wang, Lei Wang, Zhi-Wei Feng, Bin-Feng Cheng
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-08-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2018.00910/full
id doaj-e8dcc9b8ec304bc6bcaca26f857e94c6
record_format Article
spelling doaj-e8dcc9b8ec304bc6bcaca26f857e94c62020-11-25T00:06:27ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122018-08-01910.3389/fphar.2018.00910336303Fengshi Gutong Capsule Attenuates Osteoarthritis by Inhibiting MAPK, NF-κB, AP-1, and Akt PathwaysYao-Xin Gao0Hao-Heng Yu1Chuan He2Ming Li3Dan-Dan Guo4Jun-Jiang Lian5Hai-Jie Yang6Mian Wang7Lei Wang8Zhi-Wei Feng9Bin-Feng Cheng10Bin-Feng Cheng11School of Life Sciences and Technology, Xinxiang Medical University, Xinxiang, ChinaHenan Key Laboratory of Medical Tissue Regeneration, Xinxiang Medical University, Xinxiang, ChinaSchool of Life Sciences and Technology, Xinxiang Medical University, Xinxiang, ChinaSchool of Life Sciences and Technology, Xinxiang Medical University, Xinxiang, ChinaSchool of Life Sciences and Technology, Xinxiang Medical University, Xinxiang, ChinaSchool of Life Sciences and Technology, Xinxiang Medical University, Xinxiang, ChinaSchool of Life Sciences and Technology, Xinxiang Medical University, Xinxiang, ChinaSchool of Life Sciences and Technology, Xinxiang Medical University, Xinxiang, ChinaSchool of Life Sciences and Technology, Xinxiang Medical University, Xinxiang, ChinaSchool of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, ChinaSchool of Life Sciences and Technology, Xinxiang Medical University, Xinxiang, ChinaThe First Affiliated Hospital of Xinxiang Medical University, Xinxiang, ChinaBackground and purpose: Fengshi Gutong capsule (FSGTC), a traditional herbal formula, has been used clinically in China for the treatment of arthritis. However, the mechanism underlying the therapeutic effects of FSGTC on osteoarthritis (OA) has not been elucidated. The present study investigated the function and mechanisms of FSGTC in rat OA model and interleukin (IL)-1β-stimulated synovial cells.Materials and methods: Rat OA model was established by intra-articular injection containing 4% papain. IL-1β-induced SW982 cells were used as an OA cell model. Safranin-O-Fast green (S-O) and hematoxylin-eosin (HE) stainings were used to observe the changes in cartilage morphology. Enzyme-linked immunosorbent assay (ELISA) and real-time quantitative PCR (qPCR) detected the expression of inflammatory cytokines. In addition, molecular mechanisms were analyzed by Western blot in the OA cell model.Results: FSGTC treatment significantly relieved the degeneration of cartilage and reduced the contents of tumor necrosis factor-α (TNF-α) and IL-6 in the serum in papain-induced OA rats. FSGTC also reduced the protein and mRNA levels of IL-6 and IL-8 in IL-1β-stimulated SW982 cells. Moreover, it inhibited the phosphorylation levels of ERK (extracellular signal-related kinase), JNK (c-Jun N-terminal kinase), p38, Akt (protein kinase B), and c-Jun. It also decreased the extent of IκBα degradation and p65 protein translocation into the nucleus.Conclusion: The current data confirmed the protective effects of FSGTC in the rat and OA cell models. The results suggested that FSGTC reduced the production of inflammatory mediators via restraining the activation of mitogen-activated protein kinases (MAPK), nuclear factor kappa B (NF-κB), activator protein-1 (AP-1), and Akt.https://www.frontiersin.org/article/10.3389/fphar.2018.00910/fullFengshi Gutong capsuleosteoarthritisrat OA modelsynovial cellspathways
collection DOAJ
language English
format Article
sources DOAJ
author Yao-Xin Gao
Hao-Heng Yu
Chuan He
Ming Li
Dan-Dan Guo
Jun-Jiang Lian
Hai-Jie Yang
Mian Wang
Lei Wang
Zhi-Wei Feng
Bin-Feng Cheng
Bin-Feng Cheng
spellingShingle Yao-Xin Gao
Hao-Heng Yu
Chuan He
Ming Li
Dan-Dan Guo
Jun-Jiang Lian
Hai-Jie Yang
Mian Wang
Lei Wang
Zhi-Wei Feng
Bin-Feng Cheng
Bin-Feng Cheng
Fengshi Gutong Capsule Attenuates Osteoarthritis by Inhibiting MAPK, NF-κB, AP-1, and Akt Pathways
Frontiers in Pharmacology
Fengshi Gutong capsule
osteoarthritis
rat OA model
synovial cells
pathways
author_facet Yao-Xin Gao
Hao-Heng Yu
Chuan He
Ming Li
Dan-Dan Guo
Jun-Jiang Lian
Hai-Jie Yang
Mian Wang
Lei Wang
Zhi-Wei Feng
Bin-Feng Cheng
Bin-Feng Cheng
author_sort Yao-Xin Gao
title Fengshi Gutong Capsule Attenuates Osteoarthritis by Inhibiting MAPK, NF-κB, AP-1, and Akt Pathways
title_short Fengshi Gutong Capsule Attenuates Osteoarthritis by Inhibiting MAPK, NF-κB, AP-1, and Akt Pathways
title_full Fengshi Gutong Capsule Attenuates Osteoarthritis by Inhibiting MAPK, NF-κB, AP-1, and Akt Pathways
title_fullStr Fengshi Gutong Capsule Attenuates Osteoarthritis by Inhibiting MAPK, NF-κB, AP-1, and Akt Pathways
title_full_unstemmed Fengshi Gutong Capsule Attenuates Osteoarthritis by Inhibiting MAPK, NF-κB, AP-1, and Akt Pathways
title_sort fengshi gutong capsule attenuates osteoarthritis by inhibiting mapk, nf-κb, ap-1, and akt pathways
publisher Frontiers Media S.A.
series Frontiers in Pharmacology
issn 1663-9812
publishDate 2018-08-01
description Background and purpose: Fengshi Gutong capsule (FSGTC), a traditional herbal formula, has been used clinically in China for the treatment of arthritis. However, the mechanism underlying the therapeutic effects of FSGTC on osteoarthritis (OA) has not been elucidated. The present study investigated the function and mechanisms of FSGTC in rat OA model and interleukin (IL)-1β-stimulated synovial cells.Materials and methods: Rat OA model was established by intra-articular injection containing 4% papain. IL-1β-induced SW982 cells were used as an OA cell model. Safranin-O-Fast green (S-O) and hematoxylin-eosin (HE) stainings were used to observe the changes in cartilage morphology. Enzyme-linked immunosorbent assay (ELISA) and real-time quantitative PCR (qPCR) detected the expression of inflammatory cytokines. In addition, molecular mechanisms were analyzed by Western blot in the OA cell model.Results: FSGTC treatment significantly relieved the degeneration of cartilage and reduced the contents of tumor necrosis factor-α (TNF-α) and IL-6 in the serum in papain-induced OA rats. FSGTC also reduced the protein and mRNA levels of IL-6 and IL-8 in IL-1β-stimulated SW982 cells. Moreover, it inhibited the phosphorylation levels of ERK (extracellular signal-related kinase), JNK (c-Jun N-terminal kinase), p38, Akt (protein kinase B), and c-Jun. It also decreased the extent of IκBα degradation and p65 protein translocation into the nucleus.Conclusion: The current data confirmed the protective effects of FSGTC in the rat and OA cell models. The results suggested that FSGTC reduced the production of inflammatory mediators via restraining the activation of mitogen-activated protein kinases (MAPK), nuclear factor kappa B (NF-κB), activator protein-1 (AP-1), and Akt.
topic Fengshi Gutong capsule
osteoarthritis
rat OA model
synovial cells
pathways
url https://www.frontiersin.org/article/10.3389/fphar.2018.00910/full
work_keys_str_mv AT yaoxingao fengshigutongcapsuleattenuatesosteoarthritisbyinhibitingmapknfkbap1andaktpathways
AT haohengyu fengshigutongcapsuleattenuatesosteoarthritisbyinhibitingmapknfkbap1andaktpathways
AT chuanhe fengshigutongcapsuleattenuatesosteoarthritisbyinhibitingmapknfkbap1andaktpathways
AT mingli fengshigutongcapsuleattenuatesosteoarthritisbyinhibitingmapknfkbap1andaktpathways
AT dandanguo fengshigutongcapsuleattenuatesosteoarthritisbyinhibitingmapknfkbap1andaktpathways
AT junjianglian fengshigutongcapsuleattenuatesosteoarthritisbyinhibitingmapknfkbap1andaktpathways
AT haijieyang fengshigutongcapsuleattenuatesosteoarthritisbyinhibitingmapknfkbap1andaktpathways
AT mianwang fengshigutongcapsuleattenuatesosteoarthritisbyinhibitingmapknfkbap1andaktpathways
AT leiwang fengshigutongcapsuleattenuatesosteoarthritisbyinhibitingmapknfkbap1andaktpathways
AT zhiweifeng fengshigutongcapsuleattenuatesosteoarthritisbyinhibitingmapknfkbap1andaktpathways
AT binfengcheng fengshigutongcapsuleattenuatesosteoarthritisbyinhibitingmapknfkbap1andaktpathways
AT binfengcheng fengshigutongcapsuleattenuatesosteoarthritisbyinhibitingmapknfkbap1andaktpathways
_version_ 1725421939279790080